FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:711-715 August 16, 2007 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Compston, J. Related Article by Black, D. M. PubMed Citation

To the Editor: In their report on the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial, Black et al. (May 3 issue)¹ conclude that a once-yearly infusion of zoledronic acid reduces the risk of vertebral, hip, and other fractures. Although this is a well-designed and well-done study, we are concerned about the increase in atrial fibrillation in patients treated with zoledronic acid. Hypocalcemia as a cause was ruled out. There is no report of hypokalemia during the study. Another electrolyte imbalance, hypomagnesemia, is reported as a side effect of zoledronic acid² and can cause . . . [Full Text of this Article]

This article has been cited by other articles:

• Sorensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D, Cummings, S. R, Baron, J. A (2008). Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813-816 [Abstract] [Full Text]